Article

Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.

Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9063, USA.
Early Human Development (Impact Factor: 1.93). 02/2006; 82(1):23-8. DOI: 10.1016/j.earlhumdev.2005.11.001
Source: PubMed

ABSTRACT The renin-angiotensin system plays an important role in the regulation of blood pressure. The use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers both control hypertension by interruption of the production or action of angiotensin II, the major end-product of the renin-angiotensin system. The use of angiotensin converting enzyme inhibitors in pregnant women revealed serious and deleterious effects on fetal development including renal failure, renal dysplasia, hypotension, oligohydramnios, pulmonary hypoplasia, and hypocalvaria. The fetal effects of angiotensin converting enzyme inhibitors seem to be greatest during the 2nd and 3rd trimesters of pregnancy. The fetal effect of angiotensin converting enzyme inhibitors during the 1st trimester is controversial. These effects may represent the effect of hypoperfusion in the fetus and not a teratogenic effect. The effect of angiotensin receptor blockers is similar to converting enzyme inhibitors. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be avoided in all pregnant women. Alternative antihypertensive medications should be considered for use in women of childbearing years.

0 Followers
 · 
79 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension is a major public health problem rising across the globe. Inhibition of angiotensin converting enzyme (ACE) is identified as a main therapeutic target in controlling high blood pressure. The present study investigated the ACE inhibitory property of a flavonoid-rich apple peel extract (FAE), its constituents, selected flavonoids and some quercetin metabolites using a biochemical assay of ACE inhibition and a human umbilical vein endothelial cell (HUVEC) model. FAE, all the tested flavonoids except genistein, and two quercetin metabolites (quercetin-3-O-glucuronic acid and quercetin-3-O-sulfate) significantly (p<0.05) inhibited ACE. Enzyme kinetic analysis revealed that flavonoids are competitive inhibitors of ACE. In the HUVEC model, FAE, quercetin-3-O-glucoside and quercetin-3-O-glucuronic acid inhibited significantly (p<0.05) ACE activity. Overall, FAE and most of the flavonoids tested showed ACE inhibition in vitro which needs further investigations using animal and human clinical trials.
    Food Chemistry 12/2012; 135(4):2320-5. DOI:10.1016/j.foodchem.2012.07.023 · 3.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hipertenzija u trudnoći je udružena sa povišenim stepenom morbiditeta i mortaliteta majke i ploda. Oko 8% od ukupnog broja trudnoća komplikuje se hipertenzivnim poremećajima. Postoji opšta saglasnost o neophodnosti što hitnijeg lečenja budućih majki sa teškom hipertenzijom u cilju smanjenja rizika razvoja akutnih cerebrovaskularnih komplikacija. U kontroli teških oblika hipertenzije, intravenozno aplikovan labetalol ili oralno dat nifedipin su podjednako efikasni ali i udruženi sa manjim brojem neželjenih reakcija u odnosu na intravenozno ordiniran hidralazin. Opšteg stava u vezi sa potrebom lečenja blage do umerene hipertenzije u trudnoći još uvek nema, s obzirom da definitivni zaključci po pitanju odnosa potencijalnih koristi/rizika uzrokovanih primenom antihipertenzivne terapije u trudnoći još uvek ne postoje. S obzirom na bezbednu primenu u trudnoći, metildopa, labetalol i nifedipin su često korišćeni lekovi za regulaciju krvnog pritiska kod trudnica sa hipertenzijom. Kardioselektivni β blokator atenolol treba izbegavati u trudnoći jer dovodi do sniženja telesne težine na rođenju i smanjenja fetalnog rasta. Upotreba ACE inhibitora i blokatora angiotenzinskih receptora je kontraindikovana u trudnoći. Acta Medica Medianae 2008;47(3):65-72. Ključne reči: antihipertenzivni lekovi, hipertenzivni poremećaji, trudnoća Služba za kliničku i eksperimentalnu farmakologiju Kliničkog centra u Kragujevcu 1
  • Source